Foghorn Therapeutics (FHTX)
(Delayed Data from NSDQ)
$5.02 USD
-0.12 (-2.33%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $5.01 -0.01 (-0.20%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
FHTX 5.02 -0.12(-2.33%)
Will FHTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for FHTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FHTX
Alnylam (ALNY) Surges 6.0%: Is This an Indication of Further Gains?
Wall Street Analysts Predict a 130.63% Upside in Foghorn Therapeutics (FHTX): Here's What You Should Know
FHTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?
Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why
Here's Why Foghorn Therapeutics (FHTX) Looks Ripe for Bottom Fishing
Other News for FHTX
Is FHTX gaining bullish strength? 200 Day Moving Average Support shows up after slipping 2.33%
Is FHTX gaining bullish strength? Crossed Above 200 Day Moving Average shows up after soaring 7.08%
FHTX Fell Below 200 Day Moving Average on September 18
Foghorn Therapeutics (FHTX) Receives Buy Rating with $10 Target
Foghorn Therapeutics transferred with Buy rating at B. Riley